Dr Fernando Torres Andon, PhD - University of Santiago de Compostela - AECC Researcher in Nanomedicine for Cancer Immunotherapy

Dr Fernando Torres Andon

PhD

University of Santiago de Compostela

AECC Researcher in Nanomedicine for Cancer Immunotherapy

Santiago de Compostela, A Coruña | Spain

Main Specialties: Pharmacology

Additional Specialties: Nanomedicine - Cancer Immunotherapy - Nanotoxicology - Cell Death

ORCID logohttps://orcid.org/0000-0001-9235-1278


Top Author

Dr Fernando Torres Andon, PhD - University of Santiago de Compostela - AECC Researcher in Nanomedicine for Cancer Immunotherapy

Dr Fernando Torres Andon

PhD

Introduction

AECC Researcher in Nanomedicine for Cancer Immunotherapy (September 2018-present), at "University of Santiago de Compostela" (Spain) and "Istituto Clinico Humanitas" (Italy), for the project "Enhancing the effect of Cancer Immunotherapy through the Re-education of Tumor Associated Macrophages with Nanomedicines”, funded by the Asociación Española Contra el Cáncer (AECC).

Fernando Torres Andón holds a degree in Pharmacy by the University of Santiago de Compostela (Spain, 2003). He performed his European Ph.D. Thesis, “Evaluation of new compounds as potential anti-leukaemia agents” at ULPGC (Spain, 2010) under the supervision of Prof. Estévez, including a stay of three months in Breard’s lab at University Paris Sud 11 (France, 2008). This work was published in 10 scientific articles (4 as first author) in the area of cancer and cell death signalling. He was awarded as Outstanding PhD thesis in Health Sciences and Best PhD thesis in Health Sciences in 2010.

As Postdoctoral Researcher in Nanotoxicology, under the supervision of Prof. Fadeel, at Karolinska Institutet (Sweden, 2011-2013), Dr. Andón studied the Interactions between Nanomaterials and the Immune System. This work has led to the publication of 4 original manuscripts and 2 reviews in high impact journals. His work in the FP7-NANOMMUNE and FP7-MARINA implied the coordination of experimental work, collection of data (from 10 partners), writing of reports and preparation of deliverables comprising the “in vitro toxicological evaluation of nanomaterial related effects in humans” (Farcal et al 2015; and 2 additional manuscripts submitted). In January 2014, Dr. Andón has started to work on the development of novel Therapeutic Nanostructures to Target and Re-educate Tumor Associated Macrophages (TAMs). For this project, he has gathered the support of leading experts in the fields of Cancer Immunotherapy (Prof. Mantovani/Prof. Allavena ICH, Italy) and Nanomedicine (Prof. Alonso, USC, Spain) and he has received the Award to the Best Project in Oncology by Novartis Biocamp Italy in 2014 and the Marie Sk?odowska-Curie Individual European Fellowship (H2020-NANOTAM-2015-2017) and he published 2 review articles (1 corresponding author). In December 2017, Dr. Andón has been nominated Vice-coordinator of the 2-INTRATARGET project (EURONANOMEDIII), comprising 5 EU partners, which will run for the next 3 years (2018-2021).

Currently, Dr. Andón holds an AECC Investigator Research Grant for the project "Enhancing the effect of Cancer Immunotherapy through the Re-education of Tumor Associated Macrophages with Nanomedicines” (2018-2022). His research is focused on the "Design and Preclinical Evaluation of Nanomedicines for Cancer Immunotherapy: Targeting and Re-education of Tumor Associated Macrophages (TAMs)”. For this, we develop therapeutic nanostructures, loaded with immunomodulatory drugs and functionalized on their surface, to target and re-educate TAMs into antitumor macrophages, with ability to kill tumor cells, inhibit angiogenesis and promote adaptive immune responses. We study the antitumoral efficacy of these TAM-targeted-nanomedicines alone or in combination with anti-checkpoint inhibitors and/or traditional chemotherapies to achieve the effective functional and long-term reprogramming of the immunosuppressive tumor microenvironment and consequent unleash of anti-tumor immune responses. We test the efficacy of these combination therapies using appropriate in vitro and in vivo preclinical immunocompetent tumor models (i.e. lung and pancreatic cancer), with the ultimate goal to provide new solutions for patients with cancer.

Primary Affiliation: University of Santiago de Compostela - Santiago de Compostela, A Coruña , Spain

Specialties:

Additional Specialties:

Research Interests:


View Dr Fernando Torres Andon’s Resume / CV

Education

Apr 2011 - Dec 2013
Karolinska Institutet
Postdoctoral Researcher, Nanotoxicology
Jan 2007 - Jan 2010
Universidad Internacional de Andalucia
Master Degree in Bioinformatics
Jan 2004 - Jan 2010
Universidad de las Palmas de Gran Canaria
European Ph.D. in Biochemistry and Molecular Biology, Molecular Mechanisms implicated in Cell Death
Jan 2006 - Jan 2007
Instituto de Salud Carlos III
Diploma in Public Health
Jan 2006 - Jan 2007
Universidad Alfonso X El Sabio
Diploma in Pedagogical Aptitude
Jan 2004 - Jan 2007
Universidad de las Palmas de Gran Canaria
Diploma of Advanced Studies, Antitumoral Pharmacology In Vitro
Jan 2004 - Jan 2006
Universidad de las Palmas de Gran Canaria
Master Degree Courses, Collection, Preparation and Biological Assessment of Drug from Marine and Land Sources
Sep 1998 - Oct 2003
Universidade de Santiago de Compostela
Bachelor and Master Degree in Pharmacy

Experience

May 2015 - Sep 2018
Istituto Clinico Humanitas
Marie Curie Researcher in Nanomedicine for Cancer Immunotherapy
Laboratory of Cellular Immunology
Apr 2014 - May 2015
Istituto Clinico Humanitas
Postdoctoral Researcher in Nanomedicine
Jan 2014 - Apr 2014
Universidade de Santiago de Compostela - Campus Vida
Postdoc
CIMUS
Jan 2011 - Jan 2013
Karolinska Institutet
Postdoctoral Researcher in Nanotoxicology
Jan 2006 - Jan 2010
Universidad de las Palmas de Gran Canaria
Research Ph.D. Fellowship by "Gobierno Autónomo de Canarias" (Spain)
Sep 2008 - Dec 2008
Universite Paris-Sud Faculte de Pharmacie de Chatenay-Malabry
Ph.D. student - Stay of Research
Jan 2004 - Jan 2006
Universidad de las Palmas de Gran Canaria
Scientific Researcher Collaborator
Jun 2004 - Nov 2004
Pharmacy / Alfoz
Chemist (Alfoz / Spain)
Jan 2003 - Jan 2004
Universita degli Studi di Padova
Erasmus Training Period
Mar 2003 - Sep 2003
Complexo Hospitalario Universitario A Coruna
Pharmacist Training
Sep 2018
Universidade de Santiago de Compostela - Campus Vida

CIMUS

Publications

22Publications

177Reads

187Profile Views

116PubMed Central Citations

Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.

J Drug Target 2015 ;23(7-8):656-71

b Center for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela , Spain .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/1061186X.2015.1073295DOI Listing
July 2016
5 Reads
1 Citation

Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells.

Mol Carcinog 2014 Dec 13;53(12):939-50. Epub 2013 Jun 13.

Department of Biochemistry and Molecular Biology, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.22055DOI Listing
December 2014
2 Reads
5 Citations
4.810 Impact Factor

Extracellular entrapment and degradation of single-walled carbon nanotubes.

Nanoscale 2014 Jun;6(12):6974-83

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c3nr06047kDOI Listing
June 2014
7 Reads
8 Citations
7.394 Impact Factor

Mechanisms of carbon nanotube-induced toxicity: focus on pulmonary inflammation.

Adv Drug Deliv Rev 2013 Dec 7;65(15):2087-97. Epub 2013 Jun 7.

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2013.05.012DOI Listing
December 2013
4 Reads
16 Citations
15.040 Impact Factor

Biodegradation of single-walled carbon nanotubes by eosinophil peroxidase.

Small 2013 Aug 27;9(16):2721-9, 2720. Epub 2013 Feb 27.

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Nobels Väg 13, Stockholm 17177, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.201202508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039041PMC
August 2013
17 Reads
22 Citations
8.370 Impact Factor

Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials.

Acc Chem Res 2013 Mar 21;46(3):733-42. Epub 2012 Jun 21.

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ar300020bDOI Listing
March 2013
7 Reads
27 Citations
22.323 Impact Factor

Towards the clinic: intelligent design of nanomedicines for cancer treatment.

Nanomedicine (Lond) 2012 Sep;7(9):1293

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nnm.12.113DOI Listing
September 2012
4 Reads
5.413 Impact Factor

The importance of size: nanomedicine for delivery of anticancer drugs in solid tumors.

Nanomedicine (Lond) 2012 Sep;7(9):1294-5

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
September 2012
3 Reads
5.413 Impact Factor

DNA origami: self-assembled nucleic acid nanoparticles for siRNA delivery.

Nanomedicine (Lond) 2012 Sep;7(9):1295

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
September 2012
4 Reads
5.413 Impact Factor

Trimodal imaging of brain tumors using multifunctional nanoparticles.

Nanomedicine (Lond) 2012 Sep;7(9):1295-6

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
September 2012
3 Reads
5.413 Impact Factor

Perinatal nanomedicine: dendrimer-based therapy for neuroinflammatory disorders.

Nanomedicine (Lond) 2012 Sep;7(9):1294

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
September 2012
7 Reads
1 Citation
5.413 Impact Factor

5,7,3'-Trihydroxy-3,4'-dimethoxyflavone inhibits the tubulin polymerization and activates the sphingomyelin pathway.

Mol Carcinog 2011 Feb 10;50(2):113-22. Epub 2010 Dec 10.

Department of Biochemistry and Molecular Biology, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.20693DOI Listing
February 2011
5 Reads
3 Citations
4.810 Impact Factor

5,7,3'-trihydroxy-3,4'-dimethoxyflavone-induced cell death in human leukemia cells is dependent on caspases and activates the MAPK pathway.

Mol Carcinog 2010 May;49(5):464-75

Department of Biochemistry and Molecular Biology, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.20619DOI Listing
May 2010
3 Reads
6 Citations
4.810 Impact Factor

Sesquiterpene lactones from Gonospermum gomerae and G. fruticosum and their cytotoxic activities.

J Nat Prod 2008 Dec;71(12):2015-20

Departamento de Química, Universidad de Las Palmas de Gran Canaria, Campus de Tafira, 35017 Las Palmas de Gran Canaria, Canary Islands, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/np800474vDOI Listing
December 2008
5 Reads
1 Citation
3.800 Impact Factor

Induction of G2-M phase arrest and apoptosis by alpha-methylene-gamma-butyrolactones in human leukemia cells.

Cancer Lett 2008 Sep 2;269(1):139-47. Epub 2008 Jun 2.

Department of Biochemistry, University of Las Palmas de Gran Canaria, Plaza Dr. Pasteur s/n, 35016 Las Palmas de Gran Canaria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2008.04.028DOI Listing
September 2008
5 Reads
1 Citation
5.621 Impact Factor

Trifolin acetate-induced cell death in human leukemia cells is dependent on caspase-6 and activates the MAPK pathway.

Apoptosis 2008 May;13(5):716-28

Department of Biochemistry, Instituto Canario de Investigación del Cáncer (I.C.I.C.), University of Las Palmas de Gran Canaria, Plaza Dr. Pasteur s/n, 35016, Las Palmas de Gran Canaria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-008-0202-0DOI Listing
May 2008
4 Reads
5 Citations
3.685 Impact Factor

Synthesis of novel spirostanic saponins and their cytotoxic activity.

Bioorg Med Chem 2008 Feb 4;16(4):2063-76. Epub 2007 Nov 4.

Instituto de Productos Naturales y Agrobiología-C.S.I.C., Antonio González, Av. Astrofísico F. Sánchez 3, 38206 La Laguna, Tenerife, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896070095
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2007.10.089DOI Listing
February 2008
7 Reads
1 Citation
2.793 Impact Factor

Cytotoxic activities of flavonoid glycoside acetates from Consolida oliveriana.

Planta Med 2008 Feb 23;74(2):171-4. Epub 2008 Jan 23.

Instituto Universitario de Bio-Orgánica Antonio González, La Laguna, Tenerife, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2008-1034278DOI Listing
February 2008
4 Reads
1 Citation
2.152 Impact Factor

A new ceramide from Suillus luteus and its cytotoxic activity against human melanoma cells.

Chem Biodivers 2008 Jan;5(1):120-5

Instituto de Productos Naturales y Agrobiología, CSIC, Instituto Universitario de Bio-Orgánica Antonio González, Av. Astrofísico F. Sánchez 3, E-38206 La Laguna, Tenerife.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbdv.200890002DOI Listing
January 2008
3 Reads
1 Citation
1.515 Impact Factor

Isolation, structure elucidation, total synthesis, and evaluation of new natural and synthetic ceramides on human SK-MEL-1 melanoma cells.

J Med Chem 2006 Sep;49(19):5830-9

Instituto de Productos Naturales y Agrobiología, C.S.I.C., Instituto Universitario de Bio-Organica Antonio Gonzalez, Avda. Astrofísico F. Sanchez 3, 38206 La Laguna, Tenerife, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm0605334DOI Listing
September 2006
34 Reads
2 Citations
5.450 Impact Factor

Top co-authors

Fernando Torres
Fernando Torres

University of Texas Southwestern Medical Center

10
Bengt Fadeel
Bengt Fadeel

Karolinska Institutet

10
Jose Quintana
Jose Quintana

Hospital Galdakao-Usansolo (Osakidetza)-Red de Investigación en Servicios de Salud en Enfermedades Crónicas

10
Francisco Estevez
Francisco Estevez

Juan Canalejo Hospital

10
Jaime Bermejo
Jaime Bermejo

Università di Ferrara

5
Francisco Leon
Francisco Leon

National Institutes of Health

5
Ignacio Brouard
Ignacio Brouard

University of Pennsylvania

4
Fernando Torres Andón
Fernando Torres Andón

University of Santiago de Compostela

3
Sara Rubio
Sara Rubio

University of Las Palmas de Gran Canaria

2